Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

The development of novel bioresorbable vascular scaffolds market that aid patients with cardiovascular diseases is another factor driving the market for these scaffolds over the upcoming years. As an illustration, the US Food and Drug Administration approved Abbott's Absorb GT1 bioresorbable vascular scaffold in July 2016. (BVS). In patients with ischemic heart disease caused by de novo native coronary artery lesions, the product improves coronary luminal diameter over time and fully resorbs.

Read More:

https://knackersblogger.blogspot.com/2022/11/cardiovascular-diseases-is-expected-to.html

 

Login

Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe